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doi:10.1016/j.ejvs.2009.09.011Abstract Aim: This study aims to demonstrate the treatment outcomes of endovenous laser
ablation (EVLA) of incompetent small saphenous veins (SSVs) with a 980-nm diode laser.
Materials and methods: Between 1 June 2003 and 30 June 2006, 128 patients (147 limbs) with
varicose veins and reflux in the SSV on duplex ultrasound (US) examination were treated with
a 980-nm diode laser under US guidance. EVLA was performed using pulsed mode with a power
of 10 W. The pulse duration (1.5e3 s) was chosen to deliver a linear endovenous energy density
(LEED) depending on the SSV diameter measured 1.5 cm below the sapheno-popliteal junction
(SPJ) with the patient standing. For SSV diameters between 2 and 4.5 mm, the LEED applied
was 50 J cm1. The LEED was 70 J cm1 for 4.5e7 mm, 90 J cm1 for 7e10 mm. Patients were
evaluated at 1-week, 1-month, 1-year, 2-year and 3-year follow-up.
Results: The initial technical success rate was 100% in 147 patients. The SSV remained closed in
114 of 117 limbs (97%) after 1 year, all of 61 limbs after 2 years and all of 30 limbs after 3 years.
For the three SSVs where re-canalisation was observed, the diameter was greater than 9 mm.
Major complications have not been detected and, in particular, there was no deep venous
thrombosis (DVT). Ecchymoses were seen in 60% with a median duration of 2 weeks. Temporary
paraesthesia (mostly hypoaesthesia) was observed in 40% of treated legs with a median dura-
tion of 2 weeks. The maximum duration did not exceed 4 weeks. No skin discolouration, super-
ficial burn, thrombophlebitis or palpable induration was observed.
Conclusion: EVLA of the incompetent SSV with a 980-nm diode laser appears to be an
extremely safe technique. After successful treatment, there is a very low rate of re-canalisa-
tion of the SSV. Obliteration of the SSV was confirmed at 1-, 2- and 3-year follow-up; this study
suggests that this procedure will provide a lasting result.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.3 320 446 708.
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100 J. Desmytte`re et al.Venous valvular incompetence in the lower limb is
a common medical condition afflicting 25% of women and
15% of men in the United States and in Europe. Great
saphenous vein (GSV) reflux is the most common underlying
cause of significant varicose veins. Sapheno-popliteal
incompetence and short saphenous reflux, although less
common than GSV reflux, may result in symptoms of equal
severity. Surgery for the incompetent small saphenous
veins (SSV) is more challenging, with more complications
and higher recurrence rates, than for the GSV. The potential
for damage to the sural nerve with resulting neurological
deficit has deterred many vascular surgeons from stripping
the SSV routinely.1,2 Most commonly, the SSV is ligated at
the sapheno-popliteal junction (SPJ) only. Recurrence rates
of SSV after surgery are about 30e50% at 5 years.3e5
Within the past few years, minimally invasive techniques
have been developed as alternatives to surgery in an attempt
to reduce morbidity and improve recovery time. Endovenous
laser ablation (EVLA) is one of the most promising of these
new techniques. EVLA is a percutaneous minimally invasive
technique where the target vein is cannulated under duplex
US guidance and ablated with laser energy. EVLA is an
established treatment option for GSV incompetence, with
comparable success rates to conventional surgery.6e8
Several wavelengths have been used for EVLA e 810,
940, 980, 1064 and 1320 nm,9e13 with 810, 940 and 980 nm
being the most commonly used. At these wavelengths,
power is usually set between 10 and 15 W. The energy is
administered endovenously, either in a pulsed fashion
(pulse duration: 1e3 s with fibre pullback in 3- to 5-mm
increments every 2 s) or continuously with a constant
pullback of the laser fibre (pullback velocity ranging from
1 to 3 mm s1). With these parameters, the average linear
endovenous energy density (LEED), which is commonly used
to report the dose administered to the vein, ranges from
20 J cm1 to 140 J cm1.14,15 These doses induce heating of
the vein wall, which is necessary to cause collagen
contraction and destruction of endothelium. This stimu-
lates vein wall thickening leading to luminal contraction,
venous thrombosis and vein fibrosis.16 Since tumescent
anaesthesia is always used, patients feel no pain during
EVLA. Tumescent anaesthesia has two functions: it
compresses and reduces the diameter of the veins and it
acts as protective barrier, minimising the risk of heat-
related damage to adjacent tissues.17,18 Patients generally
report discomfort for 5e8 days following EVLA, which is
related to the inflammation resulting from successful
endovenous ablation (i.e., wall thickening).19 It is related
neither to the presence nor to the degree of ecchymosis nor
is it the result of laser damage to perivenous tissue.
The purpose of this study is to report on the effective-
ness and safety of EVLA of the SSV in patients from a single
centre with medium-term follow-up results.
Patients and Methods
Patients
A clinical history was taken and physical examination,
including duplex ultrasound (US)-imaging evaluation of the
superficial venous system, was performed in the limbs ofpatients with varices suspected of arising from the SSV. Study
inclusion criteria included varicose veins caused by SPJ
incompetence with SSV reflux as demonstrated by duplex US
imaging, age of at least 18 years and the ability to return for
scheduled follow-up examinations for 12, 24 and 36 months
after endovenous laser treatment. Exclusion criteria included
impalpable pedal pulses; cardio-vascular disease, inability to
ambulate; deep vein thrombosis; general poor health; preg-
nancy, nursing or plan to become pregnant during the course
of participation in the investigation; and extremely tortuous
SSVs that would not allow endovenous catheterisation and
passage of the laser fibre as identified on pre-treatment
venous duplex US mapping. Recurrent SSV after surgical
treatment and SSVs with a diameter greater than 10 mm were
also excluded. After initial consultation and evaluation,
subjects meeting the appropriate criteria were offered
surgical treatment and endovenous laser treatment. Nearly
all patients chose endovenous laser over surgical ligation and
stripping. The patients were treated at the Clinique de Vil-
leneuve d’Ascq, France (private hospital). The study protocol
was approvedby the local ethics committee.All patients gave
written, informed consent before treatment.Procedure
Duplex US (Aloka 3500, Decines, France) was performed
with the patient in the standing position to map sources of
venous reflux and then to mark the skin overlying the
incompetent portion of the SSV starting at the SPJ. The
presence of flow from the deep to superficial venous system
in perforating veins was also assessed in the thigh and calf.
The SSV diameter was measured in the standing position,
1.5 cm below the SPJ and along the SSV to select the
appropriate LEED. In an outpatient procedure room at
the hospital, the patient was placed in the prone reverse
Trendelenburg’s position for treatment of the SSV. Under
US imaging, the SSV was cannulated in the mid-to-lower
calf using a 21-gauge needle. A 0.035-inch guidewire was
passed up to the SPJ under US guidance; a 5-F introducer
was placed over the guidewire. A 600-micron optical fibre
(Osyfibre: pH-980-15-600-3, Osyris, Villeneuve d’Ascq,
France) connected to a 980-nm diode laser (Pharaon, Osy-
ris, Hellemmes, France) was passed through the introducer
to the SPJ. Its position was verified by US and by visual-
isation of the aiming beam through the skin. Duplex control
was used to guide injection of 7e8 ml aliquots of 10 ml 1%
xylocaı¨ne with epinephrine and 10 ml 1% xylocaı¨ne without
epinephrine added to 100 ml of saline. This solution was
used for the first 26 patients. For the other 102 patients, to
avoid exceeding the safe limits of local anaesthesia,
tumescence was achieved with 10 ml 1% xylocaı¨ne with
epinephrine diluted in 200 ml of saline. Injections of
tumescent anaesthesia were made into the fascial
compartment of the SSV at intervals along its length. To
reduce the amount of blood inside the vein, patients were
in a 15e20 head-down position.20
The treatment was performed as follows: the laser fibre
was placed 1e2 cm below the SPJ before treatment
commenced. The laser fibre and catheter were slowly with-
drawn in 3-mm increments using a graduated scale. Power
was set to 10 W and the pulse duration (1.5e3 s) was chosen
Table 1 CEAP classification of the 128 patients (147
limbs).
# Patients CEAP classification
2 C2 A EP AS Pr 2,3,4
1 C2 A EP AS Pr 3,4
12 C 1,2 A EP AS Pr 4
6 C2 A EP AS Pr 4
4 C 1,2 S EP AS Pr 2,3,4
6 C2 S EP AS Pr 2,3,4
1 C 1,2 S EP AS Pr 3,4
3 C2 S EP AS Pr 3,4
36 C 1,2 S EP AS Pr 4
18 C2 S EP AS Pr 4
1 C 1,2,3 A EP AS Pr 2,3,4
1 C3 A EP AS Pr 2,3,4
1 C3 A EP AS Pr 3,4
4 C 1,2,3 A EP AS Pr 4
1 C1,3 A EP AS Pr 4
2 C 3 A EP AS Pr 4
2 C 2,3 S EP AS Pr 2,3,4
1 C 1,2,3 S EP AS Pr 2,3,4
3 C3 S EP AS Pr 2,3,4
2 C3 S EP AS Pr 3,4
7 C1,3 S EP AS Pr 4
4 C 2,3 S EP AS Pr 4
7 C3 S EP AS Pr 4
1 C 1,2,4a A EP AS Pr 4
2 C 1,3,4a S EP AS Pr 2,3,4
1 C 2,3,4 b S EP AS Pr 2,3,4
1 C 1,4 a S EP AS Pr 3,4
3 C 1,2,3,4 a S EP AS Pr 4
4 C 2,4 b S EP AS Pr 4
7 C 3,4 b S EP AS Pr 4
1 C 3,4 b S EP AS Pr 2,3,4
2 C2, 4 b, 5 S EP AS Pr 4
Endovenous Laser Ablation 101to deliver a LEED appropriate to the vein diameter. For SSV
diameters between 2 and 4.5 mm, the LEED applied was
50 J cm1. The LEED was 70 J cm1 for 4.5e7 mm, 90 J cm1
for 7e10 mm. The distal part of the treated vein was moni-
tored by US imaging to prevent skin burns. A total of 39% of
the patients in this series underwent concomitant ambula-
tory phlebectomy. At the end of the procedure, compression
was applied with a compression bandage for the first 24 h,
and subsequently, a thigh length class 3 medical compression
stocking was worn for 3 weeks. Patients were instructed to
walk immediately following the procedure and to continue
their normal daily activities. All patients received a 5-day
course of non-steroidal anti-inflammatory drugs (NSAIDs)
(Piroxiam, Feldene, Pfizer Paris, France).
Follow-up examinations
Patients were evaluated functionally and clinically on day 1
after the procedure and at 1 week, 1 month, 1 year, 2 and
3 years. Patients underwent duplex scanning at 1 year, 2 and 3
years’ follow-uptoassess theclosure rate.Treatment-related
side effects and complications, including the presence of
ecchymosis, palpable induration, phlebitic reaction and pain,
were recorded. The duration of all symptoms was recorded.
Results
A total of 147 patients were seen for SSV treatment
between 1 June 2003 and 30 June 30 2006. However,
19 patients were not included into this prospective cohort
observational study: one patient due to stage III arterial
disease, two patients with cardiac disease contraindicating
prolonged Trendelenburg’s position, nine patients with an
SSV greater than 8 mm in diameter and seven patients were
excluded because catheterisation was not possible due to
excessive tortuosity of the veins. We included 128 patients
(109 female and 19 male; mean age: 49.7 years; range:
21e80 years) who underwent EVLA of incompetent SSV
segments with a 980-nm diode laser.
Among those128patients, 19were treated forbilateral SSV
reflux. Clinical severity using the Clinical, Etiological,
Anatomical and Pathological [CEAP] classification was C2 for
89 limbs, C3 for 36 limbs and C4 for 22 limbs (see details in
Table 1). As many as 39% of the patients in this series under-
went concomitant ambulatory phlebectomy. Among the 147
SSV segments, the mean SSV diameter, measured in upright
position was 5.2 SD 1.5 mm (range 3.0e10.0 mm). The mean
length of SSV treated was 18.2 SD 8.3 cm (range 3.5e49.2 cm).
Table 2 reports results with follow-up ranging from
1 year to 3 years. In the 147 limbs, the initial technical
success rate was 100%. At day 1 after the procedure and
1-week and 1-month follow-up, all SSVs were closed. The
SSVs remained closed in 114 of 117 limbs (97%) after 1 year,
in all 61 limbs after 2 years and in all 30 limbs after 3 years.
The three failures occurred in large veins (SSV diameter was
greater than 9 mm). In these patients, partial ablation of
the SSV was observed. Except for those three patients,
complete disappearance of the SSV or minimal residual
fibrous cord was noted at 1 year in all patients.
Major complications have not been detected; in partic-
ular, no deep venous thrombosis (DVT). Similarly, calf DVTswere not observed at day 1 and at any follow-up period.
Ecchymoses were seen in 60% with a median duration of 2
weeks. Transient paraesthesia (mostly hypoaesthesia) was
observed in 40% of treated legs with a median duration of 2
weeks. The maximum duration did not exceed 4 weeks. At
1-week follow-up, moderate pain was reported in 50% of the
patients. Consequently, those patients received analgesics
for one more week. No skin discolouration, superficial burn,
thrombophlebitis or palpable induration was observed.
The compliance rate for class 3 compression stockings
was 100% at 1 week and 70% at 3 weeks. This rate was
assessed using a patient questionnaire at the 1-month
follow-up appointment. No recurrent varices were seen on
clinical examination in the territory of the treated SSV at
the 1-, 2- or 3-year follow-up examination. Varicose veins
were only seen outside this region arising from other
sources than the previously treated SSV.
Discussion
Surgery for SSVs is more challenging, with more complica-
tions and higher recurrence rates than for GSVs. EVLA of
the GSV has been widely accepted as a treatment for
Table 2 Follow-up recurrence rate and complication rate following EVLA of the SSV with the 980 nm diode laser.
Follow-up
1 Week nZ 147 1 Month nZ 147 1 Year nZ 117 2 Years nZ 61 3 Years nZ 30
Occlusion rate 100% 100% 97% (114) 100% 100%
Paraesthesia 40% (58) 0% 0% 0% 0%
Pain (moderate) 50% (73) 0% 0% 0% 0%
Ecchymoses 50% (88) 0% 0% 0% 0%
102 J. Desmytte`re et al.primary varicose veins, but is less often used in the treat-
ment of SSV reflux. Reluctance of practitioners to use EVLT
in the treatment of SSV incompetence may be related to
concerns about the proximity of the sural nerve to the vein
as well as concerns about popliteal thrombosis. However, as
demonstrated by the previous studies, adequate tumes-
cence of the SSV, which theoretically separates the nerve
from the vein, can avoid sural nerve injury.21
As already proposed by Park et al., EVLA was started
from 1 cm to 1.5 cm distal to the SPJ to avoid leaving a long
residual SSV stump. Therefore, for almost all patients, EVLA
was conducted proximal to the site where the Giacomini
vein is drained.
The role of blood during the EVLA should be considered
since this may reduce the amount of light transmitted to
the vein wall. It is usually recommended to reduce the
presence of blood by emptying the vein lumen using
leg elevation (Trendelenburg’s positioning), peri-saphenous
subcutaneous tumescent saline solution infiltration and
manual compression. However, larger veins are often only
partially compressed by these measures and leg elevation
may not be enough to empty the vein. Consequently, higher
energy is necessary because some energy is deposited
in the luminal blood, creating a thrombus which can
re-canalise and cause treatment failure.15,22
The correct tumescent anaesthetic technique is essential
to ensure that this procedure is safe and painless. A
surrounding fascial envelope containing the tumescent
solution provides a margin of safety so that heat damage to
surrounding structures does not occur.23
The experience gained by our group has shown that the
energy applied during treatment was the main determinant
of success; therefore, LEED remains our choice when
comparing energy. Since thermal damage of the inner vein
wall (tunica intima) is required to achieve the tissue
destruction necessary to lead the vein to permanent
occlusion, mathematical modelling of EVLA has confirmed
that LEED should be chosen according to the vein diam-
eter,24,25 which established our policy of adjusting LEED
according to the vein diameter.
When compared with other clinical studies, LEED used for
EVLA of the SSV appears to be equivalent. When using the
980-nm diode laser, LEED reported by Park and Yim varied
between 62 J cm1 and 77 J cm1.26 Similarly, in a study
performed by another team (Park and Hwang), LEED was
adjusted to between 50 J cm1 and 60 J cm1.27 Theivacu-
mar et al. delivered a LEED of 66.3 J cm1 (54.2e71.6).28
The length of vein treated in our study (18.2 cm SD
8.3 cm) is similar to that treated by Nwaejike (18 cm, range
5e33 cm)29 and Theivacumar (17 cm, range 12e20 cm).28
We used a mean total energy (1200 J) comparable to meanenergy reported by Nwaejike: 955 J (range 135e2 800 J).
The mean SSV diameter in our study (5.2 mm SD 1.5 mm) is
comparable with the average diameter of the SSV in the
Elias’ series of 50 limbs, which was 5.8 mm.30
The clinical outcome of EVLA in the SSV has been
reported in a few articles. In Park’s series, four of 95 SSVs
re-canalised with the recurrence of reflux at 1-month
follow-up. Continued closure of the SSV was seen in 89 of
93 limbs (96%) at the 1-month follow-up, all of 87 limbs at
the 3-month follow-up, all of 82 limbs at the 6-month
follow-up, all of 77 limbs at the 1-year follow-up, all of 71
limbs at the 2-year follow-up and all of 55-limbs at the
3-year follow-up, which were available in the follow-up.27
We observed similar findings with the three recurrences
only occurring in veins greater than 9-mm diameter. Park
and Yim also observed re-canalisation of large-diameter
SSVs, in most cases greater than 9 mm.26 Since the energy
applied during treatment is the main determinant of
success, it seems that LEED was too low in those three
cases. This observation is in agreement with Timperman’s
clinical study. Greater energy delivery improves treatment
success of endovenous laser treatment.22
The incidence of ecchymoses, pain and paraesthesia was
similar to previous studies and major complications were
not reported. In our study, all paraesthesia were tempo-
rary. In Park’s study, only one patient complained of
paraesthesia at 6-months follow-up with complete resolu-
tion at 1-year follow-up.27 The ecchymosis rate in our study
was 60%. This rate was not reported in other clinical studies
involving treatment of the SSV. However, it is similar to the
rate reported by Sadick et al. (61.7%) in GSVs.31 Similarly, it
compares favourably with the ecchymosis rate (73.2%)
observed by Proebstle et al.32
We observed no case of DVT after treatment of the SSV
as was found by Park et al.27 A small number of DVTs have
been reported in other series.21,33
The principal finding in this study and other similar
clinical studies is that EVLA with a 980-nm diode laser
system, when performed under tumescent local anaes-
thesia, is clinically feasible and well tolerated.26,27 Because
the vein is accessed via a 21-gauge needle, this is a minimal
procedure, leaving virtually no scar on the patient’s skin.
Local cutaneous side effects, such as skin burns that have
been reported in less than 1% of the EVLA procedures, can
be easily avoided by injection of enough tumescent fluid.4
EVLA offers many potential advantages over conventional
surgery for SSV reflux: the procedure is performed with
on-table US imaging, giving safe and reliable identification
of the variable anatomy. Significantly, there is no neuro-
vascular injury. There is no doubt that in the next decade
there will be much debate about the optimal treatment for
Endovenous Laser Ablation 103SSV reflux. There are few good long-term outcome studies,
but those available suggest appreciable recurrence rates
within 5 years, typically from 30% to 50%.3,5 It is likely that
the role of surgery will diminish as the endovenous methods
such as EVLA become more widely used.
Conclusion
EVLA of the incompetent SSV with a 980-nm diode laser
appears to be a safe technique. After successful treatment,
there is a very low rate of re-canalisation of the SSV. Since
closure is confirmed at 1-, 2- and 3-year follow-up, our study
suggests that this procedure will provide a lasting result.Conflict of Interest/Funding
None.
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